UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 37

Sortiert nach

Phase III Trial of Bevacizumab in Combination With Gemcitabine and Erlotinib in Patients With Metastatic Pancreatic Cancer

Journal of clinical oncology, 2009-05, Vol.27 (13), p.2231-2237

2009

Volltextzugriff (PDF)

Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial

The Lancet (British edition), 2016-07, Vol.388 (10043), p.488-497

2016

Volltextzugriff (PDF)

695 Efficacy and safety of trastuzumab deruxtecan (T-DXd) with durvalumab in patients with non-small cell lung cancer (HER2 altered NSCLC) who progressed on anti-PD1/PD-L1 therapy (HUDSON)

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 1), p.A787-A787

2023

Volltextzugriff (PDF)

Blockade of insulin-like growth factor type-1 receptor with cixutumumab (IMC-A12): a novel approach to treatment for multiple cancers

Current drug targets, 2011-12, Vol.12 (14), p.2016

2011

Volltextzugriff (PDF)

An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancer

Nature medicine, 2021-05, Vol.27 (5), p.793-801

2021

Volltextzugriff (PDF)

Targeted therapies in the management of renal cell carcinoma : role of bevacizumab

Biologics, 2008-09, Vol.2 (3), p.517-530

2008

Volltextzugriff (PDF)

Safety, tolerability, and pharmacokinetics of Aurora kinase B inhibitor AZD2811: a phase 1 dose-finding study in patients with advanced solid tumours

British journal of cancer, 2023-05, Vol.128 (10), p.1906-1915

2023

Volltextzugriff (PDF)

COLUMBIA-1: a randomised study of durvalumab plus oleclumab in combination with chemotherapy and bevacizumab in metastatic microsatellite-stable colorectal cancer

British journal of cancer, 2024-07

2024

Volltextzugriff (PDF)

A phase 1 study of anti-TGFβ receptor type-II monoclonal antibody LY3022859 in patients with advanced solid tumors

Cancer chemotherapy and pharmacology, 2017-04, Vol.79 (4), p.673-680

2017

Volltextzugriff (PDF)

Targeting Aurora Kinase B with AZD2811 Enhances Venetoclax Activity in TP53-Mutant AML

Blood, 2019-11, Vol.134 (Supplement_1), p.3930-3930

2019

Volltextzugriff (PDF)

Clinical and Translational Results of a Phase II, Randomized Trial of an Anti-IGF-1R (Cixutumumab) in Women with Breast Cancer That Progressed on Endocrine Therapy

Clinical cancer research, 2016-01, Vol.22 (2), p.301-309

2016

Volltextzugriff (PDF)

Correlation of circulating tumor DNA (ctDNA), tissue-based genomic profiling and clinical efficacy in the biomarker directed Ph1b trial in metastatic bladder cancer (BISCAY)

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.4553-4553

2019

Volltextzugriff (PDF)

A phase I, open label, multicenter dose escalation study of AZD2811 nanoparticle in patients with advanced solid tumors

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.3098-3098

2019

Volltextzugriff (PDF)

A Phase I/II Study of AZD2811 Nanoparticles (NP) As Monotherapy or in Combination in Treatment-Naïve or Relapsed/Refractory AML/MDS Patients Not Eligible for Intensive Induction Therapy

Blood, 2019-11, Vol.134 (Supplement_1), p.3919-3919

2019

Volltextzugriff (PDF)

EN4-2. Tumour genomics in pts with advanced EGFRm NSCLC and post-1L osimertinib in the ORCHARD study

Japanese Journal of Lung Cancer, 2022-11, Vol.62 (6), p.566-566

2022

Volltextzugriff (PDF)

An Open-Label, Dose-Escalation Phase I Study of Anti-TYRP1 Monoclonal Antibody IMC-20D7S for Patients with Relapsed or Refractory Melanoma

Clinical cancer research, 2016-11, Vol.22 (21), p.5204-5210

2016

Volltextzugriff (PDF)

Randomized phase II trial of cixutumumab alone or with cetuximab for refractory recurrent/metastatic head and neck squamous cell carcinoma

Oral oncology, 2018-07, Vol.82, p.83-90

2018

Volltextzugriff (PDF)

A phase I study evaluating cixutumumab, a type 1 insulin-like growth factor receptor inhibitor, given every 2 or 3 weeks in Japanese patients with advanced solid tumors

Cancer chemotherapy and pharmacology, 2016-06, Vol.77 (6), p.1253-1262

2016

Volltextzugriff (PDF)

An Open-Label, Multicenter, Randomized, Phase II Study of Cisplatin and Pemetrexed With or Without Cixutumumab (IMC-A12) as a First-Line Therapy in Patients With Advanced Nonsquamous Non–Small Cell Lung Cancer

Journal of thoracic oncology, 2017-02, Vol.12 (2), p.383-389

2017

Volltextzugriff (PDF)

Phase II study of olaratumab with paclitaxel/carboplatin (P/C) or P/C alone in previously untreated advanced NSCLC

Lung cancer (Amsterdam, Netherlands), 2017-09, Vol.111, p.108-115

2017

Volltextzugriff (PDF)

Abstract CT039: Immunomodulatory effects of ceralasertib in combination with durvalumab in patients with NSCLC and progression on anti-PD-(L)1 treatment (HUDSON, NCT03334617)

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (8_Supplement), p.CT039-CT039

2023

Volltextzugriff (PDF)

Phase 1 study of narnatumab, an anti-RON receptor monoclonal antibody, in patients with advanced solid tumors

Investigational new drugs, 2017-08, Vol.35 (4), p.442-450

2017

Volltextzugriff (PDF)

An Open-label, Dose-Escalation Phase 1 Study of anti-TYRP1 monoclonal antibody IMC-20D7S for patients with relapsed or refractory melanoma

Clinical cancer research, 2016-10, Vol.22 (21), p.5204-5210

2016

Volltextzugriff (PDF)

Bevacizumab: direct anti-VEGF therapy in renal cell carcinoma

Expert review of anticancer therapy, 2008-10, Vol.8 (10), p.1545-1557

2008

Volltextzugriff (PDF)

1 – 25 von 37

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(36)
Mit Volltextzugriff
(34)

Publikationsform

Artikel
(37)

Sprache

Englisch
(36)
Japanisch
(3)

Erscheinungsjahr

n.n

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Phase III Trial of Bevacizumab in Combination With Gemcitabine and Erlotinib in Patients With Metastatic Pancreatic Cancer

Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial

695 Efficacy and safety of trastuzumab deruxtecan (T-DXd) with durvalumab in patients with non-small cell lung cancer (HER2 altered NSCLC) who progressed on anti-PD1/PD-L1 therapy (HUDSON)

Blockade of insulin-like growth factor type-1 receptor with cixutumumab (IMC-A12): a novel approach to treatment for multiple cancers

An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancer

Targeted therapies in the management of renal cell carcinoma : role of bevacizumab

Safety, tolerability, and pharmacokinetics of Aurora kinase B inhibitor AZD2811: a phase 1 dose-finding study in patients with advanced solid tumours

COLUMBIA-1: a randomised study of durvalumab plus oleclumab in combination with chemotherapy and bevacizumab in metastatic microsatellite-stable colorectal cancer

A phase 1 study of anti-TGFβ receptor type-II monoclonal antibody LY3022859 in patients with advanced solid tumors

Targeting Aurora Kinase B with AZD2811 Enhances Venetoclax Activity in TP53-Mutant AML

Clinical and Translational Results of a Phase II, Randomized Trial of an Anti-IGF-1R (Cixutumumab) in Women with Breast Cancer That Progressed on Endocrine Therapy

Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial

Correlation of circulating tumor DNA (ctDNA), tissue-based genomic profiling and clinical efficacy in the biomarker directed Ph1b trial in metastatic bladder cancer (BISCAY)

A phase I, open label, multicenter dose escalation study of AZD2811 nanoparticle in patients with advanced solid tumors

A Phase I/II Study of AZD2811 Nanoparticles (NP) As Monotherapy or in Combination in Treatment-Naïve or Relapsed/Refractory AML/MDS Patients Not Eligible for Intensive Induction Therapy

EN4-2. Tumour genomics in pts with advanced EGFRm NSCLC and post-1L osimertinib in the ORCHARD study

An Open-Label, Dose-Escalation Phase I Study of Anti-TYRP1 Monoclonal Antibody IMC-20D7S for Patients with Relapsed or Refractory Melanoma

Randomized phase II trial of cixutumumab alone or with cetuximab for refractory recurrent/metastatic head and neck squamous cell carcinoma

A phase I study evaluating cixutumumab, a type 1 insulin-like growth factor receptor inhibitor, given every 2 or 3 weeks in Japanese patients with advanced solid tumors

An Open-Label, Multicenter, Randomized, Phase II Study of Cisplatin and Pemetrexed With or Without Cixutumumab (IMC-A12) as a First-Line Therapy in Patients With Advanced Nonsquamous Non–Small Cell Lung Cancer

Phase II study of olaratumab with paclitaxel/carboplatin (P/C) or P/C alone in previously untreated advanced NSCLC

Abstract CT039: Immunomodulatory effects of ceralasertib in combination with durvalumab in patients with NSCLC and progression on anti-PD-(L)1 treatment (HUDSON, NCT03334617)

Phase 1 study of narnatumab, an anti-RON receptor monoclonal antibody, in patients with advanced solid tumors

An Open-label, Dose-Escalation Phase 1 Study of anti-TYRP1 monoclonal antibody IMC-20D7S for patients with relapsed or refractory melanoma

Bevacizumab: direct anti-VEGF therapy in renal cell carcinoma

Suchergebnisse filtern